Compare EBMT & KOD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | EBMT | KOD |
|---|---|---|
| Founded | 1922 | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 132.0M | 795.5M |
| IPO Year | N/A | 2018 |
| Metric | EBMT | KOD |
|---|---|---|
| Price | $19.04 | $23.77 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $22.67 |
| AVG Volume (30 Days) | 37.1K | ★ 720.6K |
| Earning Date | 01-27-2026 | 11-13-2025 |
| Dividend Yield | ★ 3.04% | N/A |
| EPS Growth | ★ 58.15 | N/A |
| EPS | ★ 1.72 | N/A |
| Revenue | ★ $87,531,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $6.26 | N/A |
| P/E Ratio | $11.10 | ★ N/A |
| Revenue Growth | ★ 9.36 | N/A |
| 52 Week Low | $14.35 | $1.92 |
| 52 Week High | $19.14 | $26.21 |
| Indicator | EBMT | KOD |
|---|---|---|
| Relative Strength Index (RSI) | 80.97 | 61.28 |
| Support Level | $16.05 | $21.24 |
| Resistance Level | $16.50 | $26.21 |
| Average True Range (ATR) | 0.35 | 1.68 |
| MACD | 0.26 | -0.00 |
| Stochastic Oscillator | 98.63 | 64.75 |
Eagle Bancorp Montana Inc operates as a bank holding company. It provides loan and deposit services. The company focuses on residential loans, commercial real estate loans, commercial loans, consumer loans, and home equity loan products. The bank also offers deposit accounts which include checking, savings, money market, individual retirement accounts, and certificates of deposit accounts. It is a diversified lender with a focus on residential mortgage loans, commercial real estate mortgage loans, commercial business loans, agricultural loans, and second mortgage/home equity loan products.
Kodiak Sciences Inc is a biopharmaceutical company specializing in novel therapeutics to treat high-prevalence retinal diseases. The product candidate of the company is BLA, which is a novel antibody biopolymer conjugate, in treatment-naive subjects with neovascular wet AMD. The pipeline products of the company include Tarcocimab tedromer, KSI-501, and KSI-101.